Waban, MA, United States of America

Christine Klaus

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 6.9

ph-index = 9

Forward Citations = 243(Granted Patents)


Location History:

  • Weymouth, MA (US) (2014 - 2016)
  • Waban, MA (US) (2016 - 2023)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):

Title: Christine Klaus: Innovator in Pharmaceutical Chemistry

Introduction

Christine Klaus, based in Waban, MA, is a notable inventor recognized for her contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 16 patents, she has made significant strides in the development of innovative compounds aimed at treating serious health conditions such as cancer.

Latest Patents

Among her latest innovations are patents concerning aryl- or heteroaryl-substituted benzene compounds. These compounds play a critical role in pharmaceutical compositions designed for cancer treatment. The inventions not only detail the compounds themselves but also outline methods for administering these compositions to individuals in need. Additionally, Claudia’s research includes the utilization of these compounds for non-therapeutic purposes, showcasing the versatility and significance of her work.

Career Highlights

Christine Klaus has established her career at Epizyme, Inc., a company dedicated to developing innovative therapies for cancer and other diseases. Her role has solidified her status as a key figure in the pharmaceutical industry, contributing valuable insights and advancements through her innovative inventions.

Collaborations

Throughout her career, Klaus has collaborated with talented professionals including Kenneth William Duncan and Kevin Wayne Kuntz. These collaborations have enriched her research, fostering an environment of shared knowledge and driving the advancement of their collective work in pharmaceutical innovations.

Conclusion

Christine Klaus stands out as a prominent inventor in the realm of pharmaceutical chemistry, with a focus on compounds that promise to make an impact in cancer treatment. Her ongoing work at Epizyme, Inc., along with her valuable collaborations, demonstrates her commitment to innovation and improving healthcare through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…